Association Between Body Size Phenotypes and Subclinical Atherosclerosis
Context: The underlying relationship between body mass index (BMI), cardiometabolic disorders, and subclinical atherosclerosis is poorly understood. Objective: To evaluate the association between body size phenotypes and subclinical atherosclerosis. Design: Cross-sectional. Setting: Cardiovascular d...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/15219 |
| Acceso en línea: | https://hdl.handle.net/20.500.13003/15219 |
| Access Level: | acceso abierto |
| Palabra clave: | Phenotype Prevalence Cohort Studies Atherosclerosis Risk Factors Female Male Spain Asymptomatic Diseases Cross-Sectional Studies Middle Aged Body Size Humans Adult Estudios de Cohortes Aterosclerosis Estudios Transversales Factores de Riesgo Humanos Persona de Mediana Edad Fenotipo Adulto España Femenino Masculino Enfermedades Asintomáticas Prevalencia Tamaño Corporal body size phenotypes obesity subclinical atherosclerosis cardiovascular risk |
| Sumario: | Context: The underlying relationship between body mass index (BMI), cardiometabolic disorders, and subclinical atherosclerosis is poorly understood. Objective: To evaluate the association between body size phenotypes and subclinical atherosclerosis. Design: Cross-sectional. Setting: Cardiovascular disease-free cohort. Participants: Middle-aged asymptomatic subjects (n = 3909). A total of 6 cardiometabolic body size phenotypes were defined based on the presence of at least 1 cardiometabolic abnormality (blood pressure, fasting blood glucose, triglycerides, low high-density lipoprotein cholesterol, homeostasis model assessment-insulin resistance index, high-sensitivity C-reactive protein) and based on BMI: normal-weight (NW; BMI <25), overweight (OW; BMI = 25.0-29.9) or obese (08; BMI >30.0). Main Outcome Measures: Subclinical atherosclerosis was evaluated by 2D vascular ultrasonography and noncontrast cardiac computed tomography. Results: For metabolically healthy subjects, the presence of subclinical atherosclerosis increased across BMI categories (49.6%, 58.0%, and 67.7% for NW, OW, and OB, respectively), whereas fewer differences were observed for metabolically unhealthy subjects (61.1%, 69.7%, and 70.5%, respectively). When BMI and cardiometabolic abnormalities were assessed separately, the association of body size phenotypes with the extent of subclinical atherosclerosis was mostly driven by the coexistence of cardiometabolic risk factors: adjusted OR = 1.04 (95% confidence interval [CI), 0.90-1.19) for OW and OR = 1.07 (95% CI, 0.88-1.30) for OB in comparison with NW, whereas there was an increasing association between the extent of subclinical atherosclerosis and the number of cardiometabolic abnormalities: adjusted OR = 1.21 (95% CI, 1.05-1.40),1.60 (95% Cl, 1.33-1.93), 1.92 (95% CI, 1.48-2.50), and 2.27 (95% Cl, 1.67-3.09) for 1, 2, 3, and >3, respectively, in comparison with noncardiometabolic abnormalities. Conclusions: The prevalence of subclinical atherosclerosis varies across body size phenotypes. Pharmacologic and lifestyle interventions might modify their cardiovascular risk by facilitating the transition from one phenotype to another. |
|---|